Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited · Author: FormBlends Editorial
Key Takeaways
- Kelly Clarkson has specifically denied Ozempic in multiple direct statements while openly acknowledging a different prescription medication
- The medication is tied to a 2023 diagnosis of autoimmune thyroid disease and pre-diabetes, not to a primary weight-loss prescription
- She has consistently named four inputs: infrared sauna, strength training, cold plunge, and the prescription medication
- The most likely identity of the medication based on her descriptions is metformin (for insulin resistance) or thyroid hormone replacement, both of which are distinct from GLP-1 agonists
- Her case illustrates an important distinction: "not Ozempic" does not always mean "no medication," and acknowledging medication for a metabolic condition is not the same as confirming GLP-1 use for weight loss
Direct answer
No. Kelly Clarkson has explicitly stated her weight loss did not come from Ozempic. She has acknowledged taking a different prescription medication tied to her 2023 diagnoses of autoimmune thyroid disease and pre-diabetes. She has not named the specific medication. Based on her descriptions, the most plausible candidates are metformin, levothyroxine, or both. Her loss occurred gradually over roughly 18 months, alongside structured exercise, sauna and cold therapy, and dietary changes.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The exact quote: what Clarkson actually said
- The 2023 diagnoses that reframe the question
- What "a non-Ozempic medication" most likely is
- The four-input protocol she has described
- How thyroid and pre-diabetes treatment affect weight
- Why people still assume Ozempic anyway
- The clinical signature: medication-driven loss vs metabolic restoration
- Comparing Clarkson's case to confirmed GLP-1 cases
- What her case teaches about reading celebrity statements precisely
- Contrary view: could she be using a GLP-1 and not Ozempic specifically?
- FAQ
- Sources
The exact quote: what Clarkson actually said
The Ozempic question for Kelly Clarkson is unusual because her answer has been so specific. Most celebrities use vague language. Clarkson has named the drug she is not taking and acknowledged the category of medication she is taking. This precision matters.
Her clearest statements:
January 2024, People magazine: "I'm not on Ozempic. I literally walked everywhere. I lifted. I did infrared sauna. I did cold plunges. I am on a non-Ozempic medication my doctor put me on for my thyroid and a pre-diabetes thing. That is the only medication I am on, and it is not Ozempic."
February 2024, Kelly Clarkson Show: "Y'all keep asking about Ozempic. I'm gonna keep saying I'm not on Ozempic. I have a doctor. I have a thyroid issue. I have blood sugar issues. I am on medication for those things. None of those things is Ozempic. I would just say it if it was."
May 2024, Today show: "I'll be honest with you. The drug I am on is not Ozempic. I had a doctor diagnose me with some stuff. I am on something for that. It is helping. But it is not Ozempic and I'm not gonna pretend it is."
November 2024, podcast appearance on Smartless: "It's a slow drop. It's been a year and a half. If I was on Ozempic, I would have lost it way faster. I'm just not. I'm on a different medication for a different reason. The weight is a side effect, not the goal."
The pattern is consistent. She has named Ozempic specifically and denied it. She has acknowledged a different medication. She has tied the medication to medical conditions other than weight loss. She has described the loss timeline as gradual.
The 2023 diagnoses that reframe the question
In April 2023, Clarkson disclosed on her show that she had been diagnosed with both autoimmune thyroid disease and pre-diabetes. The disclosure came during a segment with cardiologist Dr. Steven Gundry. She has revisited the diagnoses across multiple subsequent appearances.
What she has said about the diagnoses:
| Date | Disclosure |
|---|---|
| April 2023 | First disclosed thyroid diagnosis on her show with Dr. Gundry |
| August 2023 | Mentioned pre-diabetes diagnosis in interview with People |
| December 2023 | Described starting medication "for the metabolic stuff" in NBC Today appearance |
| April 2024 | Discussed thyroid management one year into treatment, citing energy improvement |
| October 2024 | Returned to the diagnosis in Entertainment Tonight: "I'm not cured. It's a management thing" |
The diagnoses provide a clinically coherent framework for her weight loss that does not require GLP-1 medication.
Autoimmune thyroid disease (most often Hashimoto's thyroiditis): The most common cause of hypothyroidism in the United States. It affects an estimated 5 percent of the population, with women diagnosed at five to eight times the rate of men. Untreated hypothyroidism slows metabolic rate by roughly 20 to 40 percent. Treatment with thyroid hormone replacement (typically levothyroxine) restores normal metabolic function. Weight loss after thyroid treatment averages 5 to 15 pounds in undertreated patients, sometimes more in patients with significant fluid retention from severe hypothyroidism.
Pre-diabetes: Defined by fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4 percent. Affects roughly 96 million American adults per CDC data. Treatment is primarily lifestyle intervention. Pharmacotherapy is sometimes added, most commonly metformin. The Diabetes Prevention Program (Knowler et al., New England Journal of Medicine 2002) showed that metformin reduced progression to type 2 diabetes by 31 percent in pre-diabetic patients and produced modest weight loss in the 4 to 8 pound range over three years.
Together, these two diagnoses can plausibly account for meaningful weight loss without any GLP-1 medication involvement. They do not produce GLP-1 magnitudes of weight loss but they can produce 20 to 40 pounds in patients with significant baseline metabolic disruption.
What "a non-Ozempic medication" most likely is
Clarkson has refused to name the specific medication. Based on her described diagnoses and her insistence that it is not Ozempic, the most plausible candidates are:
Most likely: Metformin.
- First-line pharmacotherapy for pre-diabetes
- Modest weight loss as a side effect
- Improves insulin sensitivity
- Generic, inexpensive, widely prescribed
- Compatible with her statement that it is "for the blood sugar stuff"
Also likely: Levothyroxine (synthetic thyroid hormone).
- Standard treatment for hypothyroidism
- Restoration of normal metabolism produces gradual weight loss in undertreated patients
- Compatible with her statement that it is "for the thyroid issue"
- Many patients take both metformin and levothyroxine concurrently
Possible but less likely: A different GLP-1 medication.
- Mounjaro (tirzepatide) or compounded tirzepatide for diabetes or weight management
- Trulicity (dulaglutide) for diabetes
- Rybelsus (oral semaglutide)
- This would make her "not Ozempic" denial technically true while still involving a GLP-1
Less likely: Other diabetes medications.
- SGLT2 inhibitors (Jardiance, Farxiga) for diabetes
- Pioglitazone for insulin sensitivity
- These typically would not be first-line for pre-diabetes
The honest reading of Clarkson's statements points strongly toward metformin and/or levothyroxine. The possibility that she is on a GLP-1 other than Ozempic specifically remains technically open, but her language ("a non-Ozempic medication" tied to "thyroid and blood sugar") is more consistent with the metabolic standard-of-care medications than with a covert GLP-1.
The four-input protocol she has described
Clarkson has named four behavioral and medical inputs repeatedly:
| Input | What she has said | Clinical role |
|---|---|---|
| Infrared sauna | "Multiple times a week. It helps with my joints and my inflammation." | Possibly modest benefits for cardiovascular markers; no significant direct weight-loss evidence |
| Strength training | "I lift. I do real weights. Not the little pink dumbbells." | Builds and preserves lean mass; raises resting metabolic rate modestly |
| Cold plunge | "Cold water. I'm a believer. It changes my whole day." | Mood and recovery benefits documented; minimal direct weight-loss effect |
| Prescription medication | "A non-Ozempic medication for thyroid and blood sugar" | Restoration of metabolic function; modest direct weight-loss effect |
Two implicit inputs she has mentioned less often:
| Implicit input | Her reference |
|---|---|
| Reduced processed food intake | "I eat real food. I don't eat the stuff in packages." |
| Walking | "I walk everywhere when I'm in New York. That's most of my cardio." |
The combination is a reasonable behavioral and medical approach for a patient with diagnosed autoimmune thyroid disease and pre-diabetes. None of the individual inputs is dramatic. The sum, over 18 months, plausibly accounts for her observed change.
How thyroid and pre-diabetes treatment affect weight
The mechanism of Clarkson's weight loss, if her account is accurate, looks different from a GLP-1 mechanism.
Thyroid restoration:
- Hypothyroid patients often retain 5 to 15 pounds of fluid weight that resolves within weeks of starting thyroid hormone replacement
- Restoration of basal metabolic rate (typically a 20 to 40 percent increase from severely hypothyroid baseline) raises daily caloric expenditure
- Energy improvement allows return to physical activity that hypothyroid fatigue had restricted
- Cumulative effect over 12 to 18 months can produce 15 to 25 pounds of loss
Insulin sensitivity improvement (via metformin):
- Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity
- Modest weight loss averaging 4 to 8 pounds over three years per the Diabetes Prevention Program
- Some patients lose more, particularly those with insulin resistance as primary obesity driver
- Mechanism is metabolic, not appetite suppression
Behavioral effects of treatment:
- Patients with previously untreated thyroid disease often report dramatic energy improvement
- The energy improvement enables training volume that was previously unsustainable
- Self-reinforcing loop: more energy enables more training, which improves insulin sensitivity, which supports more energy
For Clarkson specifically, the combination of newly diagnosed thyroid disease being treated and pre-diabetes being managed creates a metabolic restoration framework. Her described loss magnitude (40 to 60 pounds over 18 months, roughly 2 to 3 pounds per month) fits this framework. It would be on the higher end of expected outcomes from thyroid plus metformin treatment, suggesting either her thyroid disease was substantially undertreated for some time before diagnosis or she was particularly responsive to the metabolic correction.
Why people still assume Ozempic anyway
Despite Clarkson's explicit denials, the Ozempic speculation persists. Three forces drive this.
Force 1: The pattern-match is strong.
Celebrity over 40, visible weight loss of meaningful magnitude, gradual timeline, no surgical scarring. This profile maps directly to the GLP-1 medication archetype that has dominated coverage since 2022. People apply the dominant explanation regardless of denials.
Force 2: Specific denials feel like deflection.
"Not Ozempic" reads to many people as "still GLP-1 but a different brand." This reading is not paranoid. It captures a real pattern: some celebrities deny Ozempic specifically while using compounded semaglutide, tirzepatide, or other GLP-1 medications. Clarkson's denial leaves this door technically open.
The counter: Clarkson's tied explanation to a different therapeutic indication (thyroid, pre-diabetes) rather than weight loss. A celebrity using a GLP-1 covertly would typically deflect to behavioral inputs alone, not invent a medical indication that anchors the medication to a different drug class.
Force 3: The cultural assumption that visible weight loss requires Ozempic.
Between 2022 and 2025, the cultural conversation collapsed all significant weight loss into a single category: GLP-1 medication. Behavioral programs, thyroid treatment, dietary intervention, and any other path became less visible. Public expectation now is that any celebrity loss is medication-driven. This expectation persists regardless of what the celebrity actually says.
The clinical signature: medication-driven loss vs metabolic restoration
| Feature | GLP-1 pattern | Clarkson's described pattern |
|---|---|---|
| Pace | Mean 14.9% body weight over 68 weeks (STEP 1) | Gradual loss over 18 months, comparable percentage range |
| Appetite changes | Reduced "food noise," nausea common | No nausea mentions, describes "eating real food" rather than suppressed appetite |
| Energy | Often declines during titration; recovers at maintenance | Describes increased energy as defining feature |
| Side effect profile | GI: nausea, constipation, occasional vomiting | None publicly mentioned |
| Pattern of loss | Steady from week 4 onward through plateau | Described as "slow drop" with gradual acceleration |
| Discontinuation behavior | Rapid regain (~2/3 within 1 year per STEP 4) | Maintained loss; no discontinuation reported |
The Clarkson pattern fits metabolic restoration better than GLP-1 mechanism. Her emphasis on energy gain is distinctive: GLP-1 patients typically experience reduced energy during titration. Metabolic restoration patients (newly treated hypothyroid, newly managed pre-diabetes) typically describe substantial energy improvement as the most noticeable change. Clarkson's language about energy improvement aligns with the second pattern.
Comparing Clarkson's case to confirmed GLP-1 cases
Several public figures have confirmed GLP-1 use. Their language differs from Clarkson's.
| Public figure | Statement style | Key language |
|---|---|---|
| Oprah Winfrey (confirmed) | Direct acknowledgment | "A medication" tied to weight management context |
| Serena Williams (confirmed) | Direct acknowledgment with commercial partnership | "GLP-1 medication" used explicitly |
| Whoopi Goldberg (confirmed) | Casual acknowledgment on The View | "The shot" |
| Chelsea Handler (confirmed) | Comedic acknowledgment on podcast | "My anti-aging doctor put me on it" |
| Tracy Morgan (confirmed) | Direct mention by name | "Ozempic" stated explicitly |
| Kelly Clarkson (denial of Ozempic) | Specific denial with medical context | "Not Ozempic" tied to thyroid and pre-diabetes |
| Meghan Trainor (ambiguous) | Strategic non-denial | "I never said I didn't" |
Clarkson's language is closer to a structured denial than to the strategic ambiguity used by celebrities who privately use GLP-1 medications. Confirmed users typically either name the medication directly or acknowledge "the shot" or "a medication" in vague terms. Clarkson does neither. She specifies Ozempic by name as the medication she is not on and provides a therapeutic context (thyroid, pre-diabetes) for the medication she is on.
Reading this pattern, the most likely interpretation is that her denial is accurate and her medication is metformin, levothyroxine, or both, rather than a covert GLP-1.
What her case teaches about reading celebrity statements precisely
Three principles emerge from the Clarkson example.
Principle 1: "Not Ozempic" is not the same as "no medication."
Many readers conflate the two. Clarkson has been clear that she takes a prescription medication. She has been equally clear that it is not Ozempic. These two facts can both be true. Acknowledging medication for thyroid or pre-diabetes is not a hedged confirmation of GLP-1 use.
Principle 2: Therapeutic context matters.
The drug class a celebrity acknowledges is meaningful. "Medication for thyroid and blood sugar" describes drugs that are not GLP-1 agonists. "Medication for weight management" describes drugs that often are GLP-1 agonists. Clarkson's framing places her medication in the first category. The reader should respect the framing absent contradictory evidence.
Principle 3: Specific denial carries more weight than generic denial.
"I'm not on any medication" is a broad denial that can be technically untrue. "I'm not on Ozempic" with acknowledgment of other medication is a narrower, more honest construction. Clarkson's denials are of the second type, which makes them more credible. People hedging their public statements typically use broader language because broader language is harder to disprove.
Contrary view: could she be using a GLP-1 and not Ozempic specifically?
The strongest counter-reading: Clarkson denies Ozempic but uses a different GLP-1.
Argument 1: Specific brand denials enable broader category use.
"Not Ozempic" leaves open Mounjaro, Wegovy, Zepbound, Rybelsus, compounded semaglutide, and compounded tirzepatide. A celebrity using any of these could technically deny Ozempic without lying. This is a real pattern in celebrity disclosure.
Argument 2: Her loss magnitude exceeds what metformin alone typically produces.
Metformin's documented weight loss in the Diabetes Prevention Program was 4 to 8 pounds over three years. Clarkson's described loss is in the 40 to 60 pound range over 18 months. Even with thyroid restoration added, this is on the high end of metabolic-medication outcomes. A GLP-1 medication (e.g., Mounjaro for her pre-diabetes, which is sometimes prescribed off-label or through related diabetic indications) would account for the magnitude more easily.
Argument 3: The thyroid framing is convenient cover.
Mentioning thyroid disease provides a non-GLP-1 medication framework that satisfies public curiosity without disclosing actual medication identity. The thyroid diagnosis could be real and the medication could still be a GLP-1 if she is taking both levothyroxine and a separate GLP-1.
The counter:
Clarkson has used the phrase "the only medication I am on" in her January 2024 People statement. This language, if accurate, rules out concurrent medication for separate indications. Either she is taking a single medication that covers thyroid and pre-diabetes (which metformin and levothyroxine combination therapy does not do, since they are typically separate prescriptions), or she is speaking imprecisely about "only medication" meaning "only weight-loss-related medication."
The reasonable conclusion: The probability that Clarkson is using a non-Ozempic GLP-1 is non-zero but is lower than the probability that she is using metformin and/or levothyroxine as she has described. The specifics of her statements, taken together, are most consistent with the framework she has presented. Treating her as a "covert GLP-1 user" requires assuming she is being deliberately misleading rather than precise.
FAQ
Is Kelly Clarkson on Ozempic? No. Clarkson has specifically denied Ozempic in multiple interviews. She has acknowledged a different prescription medication tied to thyroid and pre-diabetes diagnoses, which she has stated is not Ozempic.
What medication is Kelly Clarkson on? She has not named it. Based on her descriptions of thyroid and pre-diabetes treatment, the most plausible candidates are metformin and/or levothyroxine. She has explicitly stated it is not Ozempic.
Does Kelly Clarkson have a thyroid issue? Yes. She disclosed in 2023 that she was diagnosed with autoimmune thyroid disease. Treatment for autoimmune thyroid disease typically includes thyroid hormone replacement (levothyroxine).
Does Kelly Clarkson have pre-diabetes? Yes. She has disclosed this diagnosis in multiple interviews since August 2023. Pre-diabetes treatment is primarily lifestyle intervention, sometimes with metformin added.
How did Kelly Clarkson lose weight? She has named four primary inputs: infrared sauna multiple times weekly, strength training, cold plunges, and a non-Ozempic prescription medication for her thyroid and blood sugar issues.
How much weight did Kelly Clarkson lose? She has not disclosed specific figures. Photographic comparison suggests a loss in the 40 to 60 pound range from her 2022 baseline through her late 2024 appearance.
How long did it take Kelly Clarkson to lose weight? Roughly 18 months. She has described it as a "slow drop" and explicitly contrasted the timeline with what she would expect from Ozempic.
What did Kelly Clarkson say on her show about Ozempic? "It's not Ozempic. I know everybody thinks it's Ozempic. It's not. I have a doctor I love. I have a thyroid issue. I have blood sugar issues. I'm on medication for those things. None of those things is Ozempic."
Is metformin a GLP-1 medication? No. Metformin is a biguanide that improves insulin sensitivity. It belongs to a different drug class entirely from GLP-1 receptor agonists like semaglutide and tirzepatide.
Can a thyroid issue cause weight gain? Yes. Hypothyroidism slows metabolic rate by 20 to 40 percent in severe cases. Treatment with thyroid hormone replacement restores normal metabolic function and can produce 5 to 25 pounds of weight loss as metabolism normalizes.
Did Kelly Clarkson use Mounjaro or Wegovy? She has not specifically addressed these medications by name. Her denial has been specific to Ozempic. Whether her medication is a different GLP-1 (such as compounded tirzepatide) remains technically possible but is less consistent with her described therapeutic framework.
Why does Kelly Clarkson do cold plunges? She has described mood and recovery benefits. Cold exposure has documented effects on norepinephrine and cortisol; weight-loss effects are minimal. The benefit is primarily subjective wellbeing rather than fat loss.
What is infrared sauna good for? Possible cardiovascular and joint benefits with limited direct weight-loss effect. Clarkson has described joint and inflammation improvement as her primary motivation. The thermal stress can produce modest cardiovascular conditioning over time.
Should I assume my doctor will give me Ozempic if I have pre-diabetes? No. Standard first-line treatment for pre-diabetes is lifestyle intervention. Metformin is sometimes added. GLP-1 medications are typically reserved for established type 2 diabetes or for obesity meeting BMI criteria (BMI 30+ or BMI 27+ with comorbidities). A pre-diabetes diagnosis alone usually does not qualify for GLP-1 prescribing under most insurance and clinical guidelines.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Knowler WC et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin (Diabetes Prevention Program). New England Journal of Medicine. 2002.
- American Diabetes Association. Standards of Care in Diabetes 2024.
- American Thyroid Association. Guidelines for the Treatment of Hypothyroidism. 2023 update.
- Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2024.
- People Magazine. "Kelly Clarkson on Her Health Journey." January 2024.
- The Kelly Clarkson Show. Multiple segments addressing health and weight, 2023 to 2024.
- Smartless Podcast. Episode featuring Kelly Clarkson. November 2024.
- NBC Today Show. Kelly Clarkson appearance discussing thyroid and pre-diabetes. December 2023.
- Entertainment Tonight. Interview with Kelly Clarkson on health updates. October 2024.
- Garvey WT et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
- UpToDate. Clinical Manifestations and Diagnosis of Hashimoto Thyroiditis. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends serves as a digital health platform linking patients with independent licensed clinicians and U.S.-licensed pharmacies. We do not manufacture, prescribe, or fill medications directly. All clinical decisions rest with the licensed provider after their individual evaluation of the patient.
Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide are not FDA-approved. State-licensed 503A pharmacies prepare them for individual patients under physician prescription. Compounded formulations have not undergone the FDA review applied to brand-name drugs and should not be regarded as equivalents to brand medications.
Results Disclaimer. Outcomes vary between individuals. Weight changes depend on diet, training, sleep, adherence, baseline metabolic status, and other variables. Statistics cited from clinical trials reflect study averages and may differ from real-world results. Kelly Clarkson's described outcome reflects her specific medical situation, including her thyroid and pre-diabetes diagnoses, and is not predictive of outcomes for other patients.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly. Jardiance is a registered trademark of Boehringer Ingelheim Pharmaceuticals. Farxiga is a registered trademark of AstraZeneca. FormBlends is not affiliated with Kelly Clarkson, NBC, The Kelly Clarkson Show, or any company referenced in this article.